Amgen to discontinue discounts on anemia drug: report (Reuters)
Reuters - Amgen Inc is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety, the New York Times said.
More: continued here
Recent Entries
- EU backs Greek austerity as standby aid readied (Reuters)
- Stocks rise after Fed pledges to keep rates low (AP)
- Asia stocks up as Fed, Greece news buoy confidence (AP)
- Visteon judge won’t halt benefits termination (AP)
- Oil above $82 as traders eye US supplies, OPEC (AP)
- GE sees profit, dividend up in 2011, shares climb (Reuters)
- Phillips-Van Heusen, PepsiCo are big movers (AP)
- CIT Group posts 4Q loss of $1 billion (AP)
- Fed holds rates at record lows to foster recovery (AP)
- Conn. officials feel pressure over job losses (AP)
